SCHEMBL3668795

SCHEMBL3668795

CC(C)(C)OC(=O)N(Cc1ccncc1)C1CCNCC1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 9/20 0.43
SLC6A4 P31645 9/20 0.43
SLC6A3 Q01959 7/20 0.43
HSD11B1 P28845 1/20 0.42
KCNH2 Q12809 2/20 0.41
TACR1 P25103 4/20 0.40
FNTA P49354 3/20 0.40
FNTB P49356 3/20 0.40
DCUN1D1 Q96GG9 1/20 0.40
CYP2D6 P10635 3/20 0.39
HTR2A P28223 2/20 0.39
CHRM3 P20309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5140305 0.85 TACR1 (0.55) SLC6A2SLC6A4SLC6A3KCNH2TACR1
SCHEMBL28392322 0.85 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3HSD11B1KCNH2
SCHEMBL16654305 0.81 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3HSD11B1KCNH2
SCHEMBL5037801 0.81 TACR1 (0.45) SLC6A2SLC6A4SLC6A3KCNH2TACR1
SCHEMBL20791408 0.81 SLC6A4 (0.57) SLC6A2SLC6A4SLC6A3HSD11B1KCNH2
SCHEMBL25104099 0.80 MAPKAPK2 (0.50) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL30929286 0.80 MAPKAPK2 (0.50) SLC6A2SLC6A4SLC6A3KCNH2CYP2D6
SCHEMBL10314189 0.80 MAPKAPK2 (0.38) SLC6A2SLC6A4SLC6A3HSD11B1KCNH2
SCHEMBL5042994 0.79 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3KCNH2TACR1
SCHEMBL5399569 0.79 TACR1 (0.48) SLC6A2SLC6A4SLC6A3HSD11B1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231600-A1 CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS Rigel Pharmaceuticals, Inc. (US) 2010-09-29 EP disclosed
WO-2009065131-A1 CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-22 WO disclosed